Moskin Comments on Costco’s Appeal of $19.3M Counterfeiting Judgment
29 August 2018
Bloomberg Law
Partner Jonathan Moskin was quoted in a Bloomberg Law article, “Costco Appeal of $19M Tiffany Win Could Shift Trademark Law,” about Costco’s appeal of a $19.3 million trial court judgment against it for willfully deceiving customers into believing they were buying Tiffany rings.
Moskin said the Second Circuit Court of Appeals could take a “more nuanced approach” to the Lanham Act, which governs trademark law, than trial court judge Laura Taylor Swain did. Swain ruled that the act does not require a product to bear a trademark to establish counterfeiting.
“Just because she fairly rejected that evidence isn’t fully exculpatory; it doesn’t mean there’s not extenuating circumstances,” Moskin said. “There’s so little appellate law. This may well be an opportunity for the Second Circuit to provide a more refined analysis.”
Moskin said the Second Circuit Court of Appeals could take a “more nuanced approach” to the Lanham Act, which governs trademark law, than trial court judge Laura Taylor Swain did. Swain ruled that the act does not require a product to bear a trademark to establish counterfeiting.
“Just because she fairly rejected that evidence isn’t fully exculpatory; it doesn’t mean there’s not extenuating circumstances,” Moskin said. “There’s so little appellate law. This may well be an opportunity for the Second Circuit to provide a more refined analysis.”
People
Related News
09 October 2024
In the News
Jason Mehta Weighs in on SEC Settlements, Clinical Research Fraud
Foley & Lardner LLP partner Jason Mehta commented on a recent health care litigation settlement with the U.S. Securities and Exchange Commission in the Clinical Trials Arena article, “Cassava Sciences: Phase III trials storm ahead amid controversy.”
08 October 2024
In the News
John Strom Assesses BIOSECURE ACT – 'Going to be tough to navigate'
Foley & Lardner LLP special counsel John Strom shared insight on the potential impact of the BIOSECURE ACT in the BioSpaces article, "WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow."
08 October 2024
In the News
Anil Shankar Shares Insight on Proposition 34, Impact to 340B Program
Foley & Lardner LLP partner Anil Shankar offered insight on California's Proposition 34, a ballot measure this election season, in the KCRW article, "Confused on Prop 34? It’s about the politics of rent control."